Structural basis of Escherichia coli nitroreductase NfsB triple mutants engineered for improved activity and regioselectivity toward the prodrug CB1954

Process Biochemistry

Volumn 50, Issue 11, 2015, Pages 1760-1766

  Bai, Jing ^a   Yang, Jun ^a   Zhou, Yong ^a   Yang, Qing ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

CB1954; Escherichia coli nitroreductase NfsB; Protein engineering; X ray structure

Indexed keywords

AMINO ACIDS; ENZYME ACTIVITY; ESCHERICHIA COLI; HYDROPHOBICITY;

CATALYTIC EFFICIENCIES; CB1954; HYDROPHOBIC INTERACTIONS; IMPROVED ACTIVITIES; NITROREDUCTASES; PROTEIN ENGINEERING; STEADY-STATE KINETICS; X-RAY STRUCTURE;

CRYSTAL STRUCTURE;

EID: 84946605675     PISSN: 13595113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.procbio.2015.08.012     Document Type: Article

References (28)

1. W.A. Denny Prodrug strategies in cancer therapy Eur. J. Med. Chem. 36 2001 577 595
2. T.A. Connors The choice of prodrugs for gene directed enzyme prodrug therapy of cancer Gene Ther. 2 1995 702 709
3. G.U. Dachs, M.A. Hunt, S. Syddall, D.C. Singleton, and A.V. Patterson Bystander or no bystander for gene directed enzyme prodrug therapy Molecules 14 2009 4517 4545
4. S.J. Weedon, N.K. Green, I.A. McNeish, M.G. Gilligan, V. Mautner, C.J. Wrighton, A. Mountain, L.S. Young, D.J. Kerr, and P.F. Searle Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of Escherichia coli nitroreductase Int. J. Cancer 86 2000 848 854
5. T.J. Harvey, I.M. Hennig, S.D. Shnyder, P.A. Cooper, N. Ingram, G.D. Hall, P.J. Selby, and J.D. Chester Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo Cancer Gene Ther. 18 2011 773 784
6. A.N. Lukashev, C. Fuerer, M.J. Chen, P. Searle, and R. Iggo Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954 Hum. Gene Ther. 16 2005 1473 1483
7. D. Onion, P. Patel, R.G. Pineda, N. James, and V. Mautner Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer Hum. Gene Ther. 20 2009 1249 1258
8. J.J. Roberts, F. Friedlos, and R.J. Knox CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells Biochem. Biophys. Res. Commun. 140 1986 1073 1078
9. S.O. Freytag, M. Khil, H. Stricker, J. Peabody, M. Menon, M. DePeralta-Venturina, D. Nafziger, J. Pegg, D. Paielli, S. Brown, K. Barton, M. Lu, E. Aguilar-Cordova, J.H. Kim, and I. Phase study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Cancer Res. 62 2002 4968 4976
10. P. Patel, J.G. Young, V. Mautner, D. Ashdown, S. Bonney, R.G. Pineda, S.I. Collins, P.F. Searle, D. Hull, E. Peers, J. Chester, D.M. Wallace, A. Doherty, H. Leung, L.S. Young, and N.D. James A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984] Mol. Ther. 17 2009 1292 1299
11. G.M. Anlezark, R.G. Melton, R.F. Sherwood, B. Coles, F. Friedlos, and R.J. Knox The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) - I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT) Biochem. Pharmacol. 44 1992 2289 2295
12. D. Jarrom, M. Jaberipour, C.P. Guise, S. Daff, S.A. White, P.F. Searle, and E.I. Hyde Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954 Biochemistry 48 2009 7665 7672
13. G.A. Prosser, J.N. Copp, S.P. Syddall, E.M. Williams, J.B. Smaill, W.R. Wilson, A.V. Patterson, and D.F. Ackerley Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954 Biochem. Pharmacol. 79 2015 678 687
14. J.I. Grove, A.L. Lovering, C. Guise, P.R. Race, C.J. Wrighton, S.A. White, E.I. Hyde, and P.F. Searle Generation of Esherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954 Cancer Res. 63 2003 5532 5537
15. C.P. Guise, J.I. Grove, E.I. Hyde, and P.F. Searle Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle Gene Ther. 14 2007 690 698
16. M. Jaberipour, S.O. Vass, C.P. Guise, J.I. Grove, R.J. Knox, L. Hu, E.I. Hyde, and P.F. Searle Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations Biochem. Pharmacol. 79 2010 102 111
17. P.R. Race, A.L. Lovering, S.A. White, J.I. Grove, P.F. Searle, C.W. Wrighton, and E.I. Hyde Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954 J. Mol. Biol. 368 2007 481 492
18. J. Bai, Y. Zhou, Q. Chen, Q. Yang, and J. Yang Altering the regioselectivity of a nitroreductase in the synthesis of arylhydroxylamines by structure-based engineering ChemBioChem 16 2015 1219 1225
19. S.N. Ho, H.D. Hunt, R.M. Horton, J.K. Pullen, and L.R. Pease Site-directed mutagenesis by overlap extension using the polymerase chain reaction Gene 77 1989 51 59
20. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276 1997 307 326
21. A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read Phaser crystallographic software J. Appl. Crystallogr. 40 2007 658 674
22. P.D. Adams, P.V. Afonine, G. Bunkoczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, A.J. McCoy, N.W. Moriarty, R. Oeffner, R.J. Read, D.C. Richardson, J.S. Richardson, T.C. Terwilliger, and P.H. Zwart PHENIX: a comprehensive python-based system for macromolecular structure solution Acta Crystallogr. Sect. D: Biol. Crystallogr. 66 2010 213 221
23. P. Emsley, and K. Cowtan Coot model-building tools for molecular graphics Acta Crystallogr. Sect. D: Biol. Crystallogr. 60 2004 2126 2132
24. J. Bai, J. Yang, P.Y. Liu, and Q. Yang Transformation pathway of 2,4,6-trinitrotoluene by Escherichia coli nitroreductases and improvement of activity using structure-basedmutagenesis Process. Biochem. 50 2015 705 711
25. G.N. Parkinson, J.V. Skelly, and S. Neidle Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme J. Med. Chem. 43 2000 3624 3631
26. S.W. LinWu, C.A. Wu, F.C. Peng, and A.H. Wang Structure-based development of bacterial nitroreductase against nitrobenzodiazepine-induced hypnosis Biochem. Pharmacol. 83 2012 1690 1699
27. A.L. Lovering, E.I. Hyde, P.F. Searle, and S.A. White The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7A, 1.8A and 2.4A resolution J. Mol. Biol. 309 2001 203 213
28. W.L. DeLano, The PyMOL Molecular Graphics System, Version 1.5.0.4, Schrödinger, LLC (2002)